Latest & greatest articles for insomnia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on insomnia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on insomnia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for insomnia

41. Prevalence of insomnia and sleep problems in addicted population

Prevalence of insomnia and sleep problems in addicted population Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2019 PROSPERO

42. Effectiveness of non-benzodiazepine hypnotics for older adult with insomnia: a meta-analysis and systematic review

Effectiveness of non-benzodiazepine hypnotics for older adult with insomnia: a meta-analysis and systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

43. Effectiveness and safety of moxibustion for post-stroke insomnia: protocol for a systematic review and meta-analysis

Effectiveness and safety of moxibustion for post-stroke insomnia: protocol for a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

44. Effective? Engaging? Secure? Applying the ORCHA-24 framework to evaluate apps for chronic insomnia disorder

Effective? Engaging? Secure? Applying the ORCHA-24 framework to evaluate apps for chronic insomnia disorder Effective? Engaging? Secure? Applying the ORCHA-24 framework to evaluate apps for chronic insomnia disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Effective? Engaging? Secure? Applying the ORCHA-24 framework to evaluate apps for chronic insomnia disorder Article Text Original article Effective? Engaging? Secure? Applying

2018 Evidence-Based Mental Health

45. Eszopiclone for insomnia. (PubMed)

Eszopiclone for insomnia. Insomnia is a major public health issue affecting between 6% to 10% of the adult population in Western countries. Eszopiclone is a hypnotic drug belonging to a newer group of hypnotic agents, known as new generation hypnotics, which was marketed as being just as effective as benzodiazepines for this condition, while being safer and having a lower risk for abuse and dependence. It is the aim of the review to integrate evidence from randomised controlled trials (...) and to draw conclusions on eszopiclone's efficacy and safety profile, while taking methodological features and bias risks into consideration.To assess the efficacy and safety of eszopiclone for the treatment of insomnia compared to placebo or active control.We searched the Cochrane Central Register of Controlled trials (CENTRAL), MEDLINE, Embase, PsycINFO, PSYNDEX and registry databases (WHO trials portal, ClinicalTrials.gov) with results incorporated from searches to 10 February 2016. To identify trials

2018 Cochrane

46. Melatonin (Slenyto) - insomnia (difficulty sleeping) in children and adolescents (2 to 18 years old)

Melatonin (Slenyto) - insomnia (difficulty sleeping) in children and adolescents (2 to 18 years old) Slenyto | European Medicines Agency Search Search Menu Slenyto melatonin Table of contents Authorised This medicine is authorised for use in the European Union. Overview Slenyto is a medicine for treating insomnia (difficulty sleeping) in children and adolescents (2 to 18 years old) who have: autism spectrum disorder (ASD), a range of conditions that affects the patient’s social interactions (...) areas of the brain and helping to bring about sleep. Its levels in the blood normally increase after the onset of darkness and peak in the middle of the night. Patients with developmental conditions may produce less melatonin, leading to the development of insomnia. Slenyto increases levels of melatonin in the blood, helping them to sleep. Because Slenyto releases melatonin slowly over a few hours, it mimics the natural production of melatonin in the body. What benefits of Slenyto have been shown

2018 European Medicines Agency - EPARs

47. Insomnia

Insomnia Top results for insomnia - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for insomnia The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

48. Impact of group treatment for insomnia on daytime symptomatology: Analyses from a randomized controlled trial in primary care

Impact of group treatment for insomnia on daytime symptomatology: Analyses from a randomized controlled trial in primary care People typically seek primary health care for daytime symptoms and impairments they experience in association with their insomnia. However, few studies address the question of whether insomnia treatment can improve such symptomatology.To investigate whether a nurse-led group treatment program, based on the techniques of cognitive behavioral therapy for insomnia (CBT-I (...) ), improved daytime symptomatology in primary care patients with insomnia.Fatigue (Fatigue Severity Scale [FSS]; main outcome), mood (General Health Questionnaire and Montgomery-Asberg Depression Rating Scale), health-related quality of life (Short-Form Health Survey), general daytime functioning, specific daytime symptoms (individual items from the Insomnia Severity Index and Uppsala Sleep Inventory), and dysfunctional beliefs (Dysfunctional Beliefs and Attitudes about Sleep).A randomized controlled

Full Text available with Trip Pro

2018 EvidenceUpdates

49. Antidepressants for insomnia in adults. (PubMed)

Antidepressants for insomnia in adults. Insomnia disorder is a subjective condition of unsatisfactory sleep (e.g. sleep onset, maintenance, early waking, impairment of daytime functioning). Insomnia disorder impairs quality of life and is associated with an increased risk of physical and mental health problems including anxiety, depression, drug and alcohol abuse, and increased health service use. hypnotic medications (e.g. benzodiazepines and 'Z' drugs) are licensed for sleep promotion (...) , but can induce tolerance and dependence, although many people remain on long-term treatment. Antidepressant use for insomnia is widespread, but none is licensed for insomnia and the evidence for their efficacy is unclear. This use of unlicensed medications may be driven by concern over longer-term use of hypnotics and the limited availability of psychological treatments.To assess the effectiveness, safety and tolerability of antidepressants for insomnia in adults.This review incorporated the results

Full Text available with Trip Pro

2018 Cochrane

50. Benefits and Harms of Cranial Electrical Stimulation for Chronic Painful Conditions, Depression, Anxiety, and Insomnia: A Systematic Review. (PubMed)

Benefits and Harms of Cranial Electrical Stimulation for Chronic Painful Conditions, Depression, Anxiety, and Insomnia: A Systematic Review. Cranial electrical stimulation (CES) is increasingly popular as a treatment, yet its clinical benefit is unclear.To review evidence about the benefits and harms of CES for adult patients with chronic painful conditions, depression, anxiety, and insomnia.Several databases from inception to 10 October 2017 without language restrictions and references from (...) with insomnia (n = 2), insomnia and anxiety (n = 1), or depression (n = 3) had inconclusive or conflicting results. Low-strength evidence suggested that CES does not cause serious side effects.Most trials had small sample sizes and short durations; all had high risk of bias due to inadequate blinding.Evidence is insufficient that CES has clinically important effects on fibromyalgia, headache, neuromusculoskeletal pain, degenerative joint pain, depression, or insomnia; low-strength evidence suggests modest

2018 Annals of Internal Medicine

51. Psychological interventions: Web-based cognitive behaviour therapy for insomnia shows long-term efficacy in improving chronic insomnia

Psychological interventions: Web-based cognitive behaviour therapy for insomnia shows long-term efficacy in improving chronic insomnia Web-based cognitive behaviour therapy for insomnia shows long-term efficacy in improving chronic insomnia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Web-based cognitive behaviour therapy for insomnia shows long-term efficacy in improving chronic insomnia Article Text Commentary Psychological

2018 Evidence-Based Mental Health

52. Insomnia

Insomnia Insomnia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Insomnia Last reviewed: February 2019 Last updated: April 2018 Summary One of the most common complaints reported in primary care. Unmanaged insomnia can cost over US $100 billion each year due to accidents and poor work productivity. Associated with anxiety, depression, and physical complaints. Diagnosis is made primarily by patient interview. Sleep (...) diaries, actigraphy, and polysomnography may assist in confirming diagnosis. Identification of the correct aetiology is essential, as interventions differ and may be harmful in some cases if the diagnosis is incorrect. Education regarding sleep hygiene techniques is useful to prevent chronic insomnia. The significant morbidity of insomnia indicates that it is a condition that warrants treatment. Definition As per the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), American

2018 BMJ Best Practice

53. Interventions for Insomnia Disorder

Interventions for Insomnia Disorder Interventions for Insomnia Disorder | CADTH.ca Find the information you need Interventions for Insomnia Disorder Interventions for Insomnia Disorder Last updated: December 10, 2018 Project Number: HT0003-OP0527 Product Line: Result type: Report Insomnia is a sleep disorder affecting approximately 13% of the Canadian population. People with insomnia often have difficulty falling asleep or difficulty remaining asleep. They may also wake up frequently (...) , experience early awakening, have a limited amount of sleep, or have a poor quality of sleep. Insomnia may be acute, meaning it generally starts suddenly and lasts for less than three months, or it may be chronic, meaning it lasts for a longer duration. Insomnia may affect a person’s ability to work or study, and can negatively affect their relationships with others. People with insomnia may experience a reduced quality of life because of the consequences of poor sleep. Approaches to treating insomnia

2018 CADTH - Optimal Use

54. Treatments for Insomnia: A Review of Patient and Experiences and Perspectives

Treatments for Insomnia: A Review of Patient and Experiences and Perspectives Treatments for Insomnia: A Review of Patients’ and Caregivers’ Experiences and Perspectives | CADTH.ca Find the information you need Treatments for Insomnia: A Review of Patients’ and Caregivers’ Experiences and Perspectives Treatments for Insomnia: A Review of Patients’ and Caregivers’ Experiences and Perspectives Published on: September 27, 2017 Project Number: RD0039-000 Product Line: Research Type: Drug Report (...) Type: Peer-reviewed summary with critical appraisal Result type: Report Question What are patient, caregiver, or family member experiences with and perspectives of treatment and management of insomnia? Key Message Only patient perceptions were available for review, there were no relevant data on caregiver or family member experiences. Patients’ perceptions of and engagements with pharmacotherapy tend to vary in relation to nightly levels of fatigue, daytime responsibilities and social normalization

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

55. Trajectories of change and long-term outcomes in a randomised controlled trial of internet-based insomnia treatment to prevent depression (PubMed)

Trajectories of change and long-term outcomes in a randomised controlled trial of internet-based insomnia treatment to prevent depression Insomnia treatment using an internet-based cognitive-behavioural therapy for insomnia (CBT-I) program reduces depression symptoms, anxiety symptoms and suicidal ideation. However, the speed, longevity and consistency of these effects are unknown.To test the following: whether the efficacy of online CBT-I was sustained over 18 months; how rapidly the effects (...) of CBT-I emerged; evidence for distinct trajectories of change in depressive symptoms; and predictors of these trajectories.A randomised controlled trial compared the 6-week Sleep Healthy Using the Internet (SHUTi) CBT-I program to an attention control program. Adults (N=1149) with clinical insomnia and subclinical depression symptoms were recruited online from the Australian community.Depression, anxiety and insomnia decreased significantly by week 4 of the intervention period and remained

Full Text available with Trip Pro

2017 BJPsych open Controlled trial quality: uncertain

56. Management of Insomnia Disorder in Adults: Current State of the Evidence

Management of Insomnia Disorder in Adults: Current State of the Evidence Management of Insomnia Disorder in Adults: Current State of the Evidence Focus of This Summary This is a summary of a systematic review that evaluated current evidence regarding the effectiveness, comparative effectiveness, and adverse effects of management strategies for insomnia disorder in adults. The systematic review synthesized evidence from 169 randomized controlled trials and 12 observational studies published (...) through January 2015. The full report, listing all studies, is available at www.effectivehealthcare.ahrq.gov/insomnia/. This summary is provided to assist in informed clinical decisionmaking. However, reviews of evidence should not be construed to represent clinical recommendations or guidelines. Background Insomnia involves dissatisfaction with sleep quantity or quality and is associated with difficulty initiating sleep, maintaining sleep, returning to sleep after early morning waking

2017 Effective Health Care Program (AHRQ)

57. Cognitive behavioral therapy for insomnia in Parkinson’s disease: a case series (PubMed)

Cognitive behavioral therapy for insomnia in Parkinson’s disease: a case series Chronic insomnia is common in patients with Parkinson's disease. There are limited data to guide its treatment in this patient population, especially in regards to non-pharmacologic interventions, some of which are highly effective in the non-Parkinson's disease population. The aim of this study is to describe a series of Parkinson's disease patients who underwent cognitive behavioral therapy for insomnia (CBTi (...) of CBTi (range 5-12). Significant increases in sleep efficiency (p = 0.02) and decreases in number of awakenings per night (p = 0.02) were found. Our data provide preliminary evidence that cognitive behavioral therapy is an effective treatment for insomnia in Parkinson's disease, and is well tolerated and well received by patients. Given the limited data supporting use of medications to treat chronic insomnia in Parkinson's disease, combined with their risks, randomized trials to demonstrate

Full Text available with Trip Pro

2017 NPJ Parkinson's disease

58. Tai Chi Chih Compared With Cognitive Behavioral Therapy for the Treatment of Insomnia in Survivors of Breast Cancer: A Randomized, Partially Blinded, Noninferiority Trial

Tai Chi Chih Compared With Cognitive Behavioral Therapy for the Treatment of Insomnia in Survivors of Breast Cancer: A Randomized, Partially Blinded, Noninferiority Trial Purpose Cognitive behavioral therapy for insomnia (CBT-I) and Tai Chi Chih (TCC), a movement meditation, improve insomnia symptoms. Here, we evaluated whether TCC is noninferior to CBT-I for the treatment of insomnia in survivors of breast cancer. Patients and Methods This was a randomized, partially blinded, noninferiority (...) trial that involved survivors of breast cancer with insomnia who were recruited from the Los Angeles community from April 2008 to July 2012. After a 2-month phase-in period with repeated baseline assessment, participants were randomly assigned to 3 months of CBT-I or TCC and evaluated at months 2, 3 (post-treatment), 6, and 15 (follow-up). Primary outcome was insomnia treatment response-that is, marked clinical improvement of symptoms by the Pittsburgh Sleep Quality Index-at 15 months. Secondary

Full Text available with Trip Pro

2017 EvidenceUpdates

59. Medical Cannabis or Cannabinoids for the Treatment of Insomnia Disorder in Adults: Clinical Effectiveness and Guidelines

Medical Cannabis or Cannabinoids for the Treatment of Insomnia Disorder in Adults: Clinical Effectiveness and Guidelines Medical Cannabis or Cannabinoids for the Treatment of Insomnia Disorder in Adults: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Medical Cannabis or Cannabinoids for the Treatment of Insomnia Disorder in Adults: Clinical Effectiveness and Guidelines Medical Cannabis or Cannabinoids for the Treatment of Insomnia Disorder in Adults: Clinical (...) Effectiveness and Guidelines Published on: June 26, 2017 Project Number: RB1113-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of medical cannabis or cannabinoids for the treatment of insomnia disorder in adults? What are the evidence-based guidelines regarding the use of medical cannabis or cannabinoids for the treatment of insomnia disorder in adults? Key Message One randomized controlled trial and one non-randomized

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

60. Current Practice Analysis: Interventions for Insomnia Disorder

Current Practice Analysis: Interventions for Insomnia Disorder Current Practice Analysis: Interventions for Insomnia Disorder (Optimal Use Project, June 2017) | CADTH.ca CADTH Document Viewer Current Practice Analysis: Interventions for Insomnia Disorder (Optimal Use Project, June 2017) Table of Contents Search this document Current Practice Analysis: Interventions for Insomnia Disorder (Optimal Use Project, June 2017) June 2017 Introduction CADTH studied the use of interventions to treat (...) insomnia disorder (acute and chronic) in Canadian primary care practice. The study investigated current practices and trends in drug and non-drug therapies for patients with insomnia disorder from the perspective of family physicians, nurse practitioners, and pharmacists. The findings are based on a targeted literature review as well as on the results of qualitative research from surveys of primary care practitioners. This report presents a summary of findings. Issue Insomnia disorder is a common

2017 CADTH - Optimal Use